Clinical experience and prognosis analysis of 48 cases of intraductal carcinoma of the prostate: a single-center retrospective study
10.3969/j.issn.1009-8291.2025.03.008
- VernacularTitle:前列腺导管内癌48例治疗经验及预后分析：一项单中心回顾性研究
- Author:
Caixiang ZHANG
1
;
Youquan ZHAO
1
;
Xuejing WEI
2
Author Information
1. Department of Urology, Institute of Urology, Beijing Municipal Health Commission, Beijing 100050, China
2. Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Journal Article
- Keywords:
intraductal carcinoma of the prostate;
radical prostatectomy;
endocrinotherapy;
biochemical recurrence
- From:
Journal of Modern Urology
2025;30(3):223-226
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze and summarize the clinical characteristics and treatment methods of intraductal carcinoma of the prostate (IDC-P)，so as to improve the diagnosis and treatment of this disease. Methods: The clinical data of 48 IDC-P patients treated in Beijing Friendship Hospital during May 2017 and Mar.2024 were retrospectively analyzed.IDC-P was diagnosed by pathology in 27 cases by prostate puncture，in 2 cases by transurethral plasma resection of the prostate，and in 19 cases by radical prostatectomy.Of all patients，24 received radical prostatectomy，21 received direct endocrinotherapy，2 received prostate radioactive
I implantation brachytherapy combine with androgen deprivation therapy，and 1 patient was observed and waiting.Kaplan-Meier method was used to analyze the main prognostic indicators. Results: One patient was lost to follow-up.Of the 47 patients followed up，24 underwent radical prostatectomy，of whom 22 underwent postoperative endocrinotherapy，and 10 had biochemical recurrence; 23 patients only received endocrinotherapy，and 14 of them had biochemical recurrence.Altogether 45 patients received endocrinotherapy，including 33 who received standardized treatment (21 had biochemical recurrence) and 12 who received novel treatment (3 had biochemical recurrence).Survival analysis showed that radical prostatectomy had no significant impact on the biochemical recurrence after endocrinotherapy (P=0.250).Novel endocrinotherapy could delay biochemical recurrence compared with standardized endocrinotherapy (P=0.003). Conclusion: Abiraterone or enzalutamide therapy can reduce the risk of biochemical recurrence，but further studies are needed to determine the optimal treatment for IDC-P patients.
